Adamas Pharmaceuticals (NASDAQ:ADMS) shares fell 0% on Friday . The company traded as low as $22.74 and last traded at $22.94. 505,788 shares changed hands during trading, a decline of 52% from the average session volume of 1,050,533 shares. The stock had previously closed at $22.94.
ADMS has been the subject of a number of research reports. Leerink Swann initiated coverage on Adamas Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating and a $31.00 price objective for the company. ValuEngine raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 10th. Bank of America initiated coverage on Adamas Pharmaceuticals in a research report on Tuesday, March 27th. They set a “buy” rating and a $39.00 price objective for the company. Finally, Zacks Investment Research cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $42.89.
The company has a debt-to-equity ratio of 1.55, a current ratio of 10.79 and a quick ratio of 10.69.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.84 million. During the same period in the prior year, the company earned ($0.68) earnings per share. Adamas Pharmaceuticals’s revenue was up 1435.1% on a year-over-year basis. research analysts expect that Adamas Pharmaceuticals will post -5.87 EPS for the current year.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 4,541 shares of the business’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total value of $116,930.75. Following the completion of the sale, the chief executive officer now owns 182,610 shares of the company’s stock, valued at $4,702,207.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Rajiv Patni sold 1,252 shares of the business’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total value of $32,476.88. Following the completion of the sale, the insider now directly owns 21,515 shares of the company’s stock, valued at approximately $558,099.10. The disclosure for this sale can be found here. Insiders sold 6,360 shares of company stock valued at $164,138 in the last ninety days. Insiders own 29.00% of the company’s stock.
Several large investors have recently made changes to their positions in ADMS. Point72 Asset Management L.P. lifted its position in shares of Adamas Pharmaceuticals by 639.3% in the third quarter. Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company’s stock worth $17,998,000 after buying an additional 735,165 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Adamas Pharmaceuticals by 632.7% in the fourth quarter. Deutsche Bank AG now owns 506,369 shares of the specialty pharmaceutical company’s stock worth $17,159,000 after buying an additional 437,263 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of Adamas Pharmaceuticals in the fourth quarter worth about $7,356,000. UBS Asset Management Americas Inc. acquired a new stake in shares of Adamas Pharmaceuticals in the fourth quarter worth about $6,680,000. Finally, Ardsley Advisory Partners acquired a new position in shares of Adamas Pharmaceuticals during the 4th quarter worth about $5,253,000. 77.25% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Adamas Pharmaceuticals (ADMS) Stock Price Down 0%” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/adamas-pharmaceuticals-adms-stock-price-down-0.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.